Re: Dużo dobrych wiadomości

We are excited to inform you that SEL24 (MEN1703) clinical data from the DIAMOND-01 trial will be presented at the upcoming ASCO and EHA Virtual Meetings 2021.
SEL24 (MEN1703) is a Ryvu Therapeutics discovered and developed first in class, orally available, dual PIM/FLT3 inhibitor, currently developed by Menarini Group and evaluated in the DIAMOND-01 trial for the treatment of Acute Myeloid Leukemia.
 
In the dose-escalation part of the DIAMOND-01 trial, SEL24/MEN1703 demonstrated a manageable safety profile up to the recommended dose (RD) of 125 mg/day, along with initial evidence of anti-leukemic activity in a single agent setting. 
 
Data reported in the ASCO and EHA posters refer to patients enrolled in Phase II, cohort expansion part of the study, which confirmed the manageable safety profile of the drug at the RD and showed preliminary single-agent efficacy in r/r AML, particularly in patients with IDH mutant disease either naïve or previously exposed to IDH inhibitors. These results warrant further investigation of SEL24 (MEN1703) in AML, with a potential focus in the IDH mutated subset. 
 
It is very encouraging data that provides a strong rationale for progressing into the clinical development of SEL24 (MEN1703), potentially focusing on a molecularly defined subset of patients, in line with the precision oncology approach.